IL2RA and smallpox: Among patients in IL2-R blocker group, 16.6% developed CMV infection, 8.2% developed BK-virus infection and no patient developed smallpox, in control group 12.6% developed CMV infection, 3.9% developed BK-virus and 2% Varicella toward the end of the first year.